CD38 and Miyoshi myopathy: Based on the absence/presence of differentiated lineage markers, we observed the expansion of stem/early progenitors (CD34+CD38−− cells) accompanied by a reduction of late progenitors (CD34+CD38+ cells; p = 0.05; Figures 3B,C) in the MM-EV treated compared to control HPSCs.